Compositions and methods for treatment of diseases and disorders associated with cytokine signaling

Abstract

Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.

1 - 2 . (canceled) 
     
     
         3 . A method of treating an autoimmune disorder, wherein the autoimmune disorder is not arthritis, the method comprising administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22. 
     
     
         4 . The method of  claim 3 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22. 
     
     
         5 . The method of  claim 4 , wherein the antibody that specifically binds IL-22 is (a) an antibody produced by a hybridoma selected from 3F11.3 ATCC Accession No. PTA-7312), hybridoma 11H4.4 (ATCC Accession No. PTA-7315), and hybridoma 8E11.9 (ATCC Accession No. PTA-7319); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c). 
     
     
         6 . The method of  claim 3 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22R. 
     
     
         7 . The method of  claim 6 , wherein the antibody that specifically binds IL-22R is (a) an antibody produced by a hybridoma selected from 7E9 (ATCC Accession No. PTA-7313), hybridoma 8A12 (ATCC Accession No. PTA-7318), and hybridoma 8H11 (ATCC Accession No. PTA-7317); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c). 
     
     
         8 . The method of  claim 3 , wherein the IL-22 antagonist is IL-22BP. 
     
     
         9 . The method of  claim 3 , wherein the autoimmune disorder is inflammatory bowel disease. 
     
     
         10 . The method of  claim 3 , wherein the autoimmune disorder is psoriasis. 
     
     
         11 . The method of  claim 10 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22. 
     
     
         12 . (Original The method of  claim 11 , further comprising administering at least one antibody selected from an antibody that specifically binds IL20Ra, an antibody that specifically binds IL20Rb, and an antibody that specifically binds IL-22R. 
     
     
         13 . The method of  claim 10 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22R. 
     
     
         14 . The method of  claim 13 , further comprising administering at least one antibody selected from an antibody that specifically binds IL-22, an antibody that specifically binds IL20Ra, and an antibody that specifically binds IL20Rb. 
     
     
         15 . A method of treating inflammation, wherein the inflammation is not arthritic inflammation, the method comprising administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22. 
     
     
         16 . The method of  claim 15 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22. 
     
     
         17 . The method of  claim 16 , wherein the antibody that specifically binds IL-22 is (a) an antibody produced by a hybridoma selected from 3F11.3 (ATCC Accession No. PTA-7312), hybridoma 11H4.4 (ATCC Accession No. PTA-7315), and hybridoma 8E11.9 (ATCC Accession No. PTA-7319); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c). 
     
     
         18 . The method of  claim 15 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22R. 
     
     
         19 . The method of  claim 18 , wherein the antibody that specifically binds IL-22R is (a) an antibody produced by a hybridoma selected from 7E9 (ATCC Accession No. PTA-7313), hybridoma 8A12 (ATCC Accession No. PTA-7318), and hybridoma 8H11 (ATCC Accession No. PTA-7317); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c). 
     
     
         20 . The method of  claim 15 , wherein the IL-22 antagonist is IL-22BP. 
     
     
         21 . The method of  claim 15 , wherein the inflammation is autoimmune inflammation. 
     
     
         22 . The method of  claim 15 , wherein the inflammation is skin inflammation. 
     
     
         23 . The method of  claim 15 , wherein the inflammation is chronic inflammation. 
     
     
         24 . A method of inhibiting tumor progression, the method comprising administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22. 
     
     
         25 . The method of  claim 24 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22. 
     
     
         26 . The method of  claim 25 , wherein the antibody that specifically binds IL-22 is (a) an antibody produced by a hybridoma selected from 3F11.3 (ATCC Accession No. PTA-7312), hybridoma 11H4.4 (ATCC Accession No. PTA-7315), and hybridoma 8E11.9 (ATCC Accession No. PTA-7319); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c). 
     
     
         27 . The method of  claim 25 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22R. 
     
     
         28 . The method of  claim 27 , wherein the antibody that specifically binds IL-22R is (a) an antibody produced by a hybridoma selected from 7E9 (ATCC Accession No. PTA-7313), hybridoma 8A12 (ATCC Accession No. PTA-7318), and hybridoma 8H11 (ATCC Accession No. PTA-7317); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c). 
     
     
         29 . The method of  claim 24 , wherein the IL-22 antagonist is IL-22BP. 
     
     
         30 . A method of stimulating an IL-23-mediated signaling pathway in a biological system, the method comprising providing an IL-22 agonist to the biological system. 
     
     
         31 . The method of  claim 30 , wherein the IL-22 agonist is IL-22. 
     
     
         32 . A method of inhibiting an IL-23-mediated signaling pathway in a biological system, the method comprising providing an IL-22 antagonist to the biological system. 
     
     
         33 . The method of  claim 32 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22. 
     
     
         34 . The method of  claim 32 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22R. 
     
     
         35 . A method of stimulating a Th IL-17  cell function, the method comprising exposing a Th IL-17  cell to an IL-22 agonist. 
     
     
         36 . The method of  claim 35 , wherein the IL-22 agonist is IL-22. 
     
     
         37 . A method of inhibiting a Th IL-17  cell function, the method comprising exposing a Th IL-17  cell to an IL-22 antagonist. 
     
     
         38 . The method of  claim 37 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22. 
     
     
         39 . The method of  claim 37 , wherein the IL-22 antagonist is an antibody that specifically binds IL-22R.